A Study to Detect Liver Enzyme Dysfunction among Patients on First Line Anti-Tubercular Drugs from RNTCP during the Course of Anti-TB Treatment

Globally, an estimated 10.0 million people developed Tuberculosis in 2017. Side effects and toxicity of the first line anti-tubercular drugs were hepatotoxicity, skin rash, and joint pain. If hepatotoxicity develops on reintroduction of treatment with the same regimen, then treatment should be started with hepato-safe regimen. Majority of the reports have used an elevated Alanine Transaminase (ALT) or Aspartate Transaminase (AST) of 3 times upper limit of normal range (ULN) with symptoms attributable to liver injury or 5 times ULN of ALT or AST without symptoms to define hepatotoxicity. Due to paucity of studies regarding adaptive response, this study was conducted to find out the proportion of anti-tubercular drug (ATD) induced hepatitis during Anti-TB treatment and frequency of adaptive changes in Liver Enzymes during the course of anti TB treatment. METHODS 116 patients who were diagnosed to have Pulmonary (PTB)/ Extrapulmonary (EPTB) tuberculosis at Outpatient & In-Patients of Department of Chest Medicine, Burdwan Medical College & Hospital, for eleven months after fulfilling the inclusion and exclusion criteria were included in the study. Treatment was given as per guidelines of Revised National TB Control Program.